Richard G. Doveston

Richard G. Doveston

Auto-generated profile, based on publicly available information

Richard G. Doveston

Institute of Structural and Chemical Biology and School of Chemistry University of Leicester Leicester LE1 7RH UK

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 October 2017 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
LSLoes M. Stevers
Loes M. Stevers
ESEline Sijbesma
Eline Sijbesma
MBMaurizio Botta
Maurizio Botta
CMCarol MacKintosh
Carol MacKintosh
Tomas ObsilTomas Obsil
Tomas Obsil
COChristian Ottmann
Christian Ottmann
Direct interactions between proteins are essential for the regulation of their functions in biological pathways. Targeting the complex network of protein-protein interactions (PPIs) has now been widely recognized as an attractive means to therapeutically intervene in disease states. Even though this is a challenging endeavor and PPIs have long been regarded as ‘undruggable’ targets, the last two decades have seen an increasing number of successful examples of PPI modulators resulting in a growing interest in this field. PPI modulation requires novel approaches and the integrated efforts of multiple disciplines to be a fruitful strategy. This Perspective focuses on the hub protein 14-3-3, which has several hundred identified protein interaction partners and is therefore involved in a wide range of cellular processes and diseases. Here, we aim to provide an integrated overview of the approaches explored for the modulation of 14-3-3 PPIs and review the examples resulting from these efforts in both inhibiting and stabilizing specific 14-3-3 protein complexes by small molecules, peptide-mimetics and natural products.

6 July 2017 in Expert Opinion on Drug Discovery
Verified
Journal Article
Open access
SASebastian A. Andrei
Sebastian A. Andrei
ESEline Sijbesma
Eline Sijbesma
MHMichael Hann
Michael Hann
JDJeremy Davis
Jeremy Davis
GOGavin O’mAhony
Gavin O’mAhony
COChristian Ottmann
Christian Ottmann
Introduction: PPIs are involved in every disease and specific modulation of these PPIs with small molecules would significantly improve our prospects of developing therapeutic agents. Both industry and academia have engaged in the identification and use of PPI inhibitors. However in comparison, the opposite strategy of employing small-molecule stabilizers of PPIs is underrepresented in drug discovery. Areas covered: PPI stabilization has not been exploited in a systematic manner. Rather, this concept validated by a number of therapeutically used natural products like rapamycin and paclitaxel has been shown retrospectively to be the basis of the activity of synthetic molecules originating from drug discovery projects among them lenalidomide and tafamidis. Here, the authors cover the growing number of synthetic small-molecule PPI stabilizers to advocate for a stronger consideration of this as a drug discovery approach. Expert opinion: Both the natural products and the growing number of synthetic molecules show that PPI stabilization is a viable strategy for drug discovery. There is certainly a significant challenge to adapt compound libraries, screening techniques and downstream methodologies to identify, characterize and optimize PPI stabilizers, but the examples of molecules reviewed here in our opinion justify these efforts.

5 May 2016 in Chemical Communications
Verified
Journal Article
Open access
PDF file
ICIgnacio Colomer
Ignacio Colomer
CEChristopher J. Empson
Christopher J. Empson
PCPhilip Craven
Philip Craven
Zachary OwenZachary Owen
Zachary Owen
RDRichard G. Doveston
Richard G. Doveston
ANAdam Nelson
Adam Nelson
LLAMA was used to assess the lead-likeness of scaffolds prepared via complementary cyclisations of hex-2-ene-1,6-diamine derivatives.

18 November 2014 in Organic & Biomolecular Chemistry
Verified
Journal Article
Open access
PDF file
RDRichard G. Doveston
Richard G. Doveston
PTPaolo Tosatti
Paolo Tosatti
MDMark Dow
Mark Dow
DFDaniel J. Foley
Daniel J. Foley
HLHo Yin Li
Ho Yin Li
ANAdam Nelson
Adam Nelson
Sourcing large numbers of lead-like compounds is a major challenge; a unified synthetic approach enabled the efficient synthesis of 52 diverse lead-like molecular scaffolds from just 13 precursors.

23 March 2017 in Biochemical Journal
Verified
Journal Article
Closed access
PDF file
LSLoes M. Stevers
Loes M. Stevers
RVRens M.J.M. de Vries
Rens M.J.M. de Vries
RDRichard G. Doveston
Richard G. Doveston
LMLech-Gustav Milroy
Lech-Gustav Milroy
LBLuc Brunsveld
Luc Brunsveld
COChristian Ottmann
Christian Ottmann
Binding of 14-3-3 proteins to leucine-rich repeat protein kinase 2 (LRRK2) is known to be impaired by many Parkinson's disease (PD)-relevant mutations. Abrogation of this interaction is connected to enhanced LRRK2 kinase activity, which in turn is implicated in increased ubiquitination of LRRK2, accumulation of LRRK2 into inclusion bodies and reduction in neurite length. Hence, the interaction between 14-3-3 and LRRK2 is of significant interest as a possible drug target for the treatment of PD. However, LRRK2 possesses multiple sites that, upon phosphorylation, can bind to 14-3-3, thus rendering the interaction relatively complex. Using biochemical assays and crystal structures, we characterize the multivalent interaction between these two proteins.

6 October 2017 in Chemistry – A European Journal
Verified
Journal Article
Open access
PDF file
DFDaniel J. Foley
Daniel J. Foley
PCPhilip G. E. Craven
Philip G. E. Craven
PCPatrick Collins
Patrick Collins
RDRichard G. Doveston
Richard G. Doveston
AAAnthony Aimon
Anthony Aimon
ANAdam Nelson
Adam Nelson
The productive exploration of chemical space is an enduring challenge in chemical biology and medicinal chemistry. Natural products are biologically relevant, and their frameworks have facilitated chemical tool and drug discovery. A “top‐down” synthetic approach is described that enabled a range of complex bridged intermediates to be converted with high step efficiency into 26 diverse sp3‐rich scaffolds. The scaffolds have local natural product‐like features, but are only distantly related to specific natural product frameworks. To assess biological relevance, a set of 52 fragments was prepared, and screened by high‐throughput crystallography against three targets from two protein families (ATAD2, BRD1 and JMJD2D). In each case, 3D fragment hits were identified that would serve as distinctive starting points for ligand discovery. This demonstrates that frameworks that are distantly related to natural products can facilitate discovery of new biologically relevant regions within chemical space.